(MedPage Today) — Smaller doses OK’d for certain acute myeloid leukemia indications

Related Links:

Publication date: Available online 21 July 2018Source: Leukemia Research ReportsAuthor(s): Passant Badr, Ghada M Elsayed, Dalia Negm Eldin, Bahia Y Riad, Hamdy NayeraAbstractWe have investigated the frequency and the effect of KIT mutations on the outcome of patients with CBF-AML. 69 patients (35 pediatrics and 34 adults) with CBF-AML were enrolled in the study. The frequency of KIT mutations was higher in adults compared to pediatrics (22.9% and 14.7%, p=0.38) respectively. Leukocytosis ≥20 × 109 /L was significantly associated with pediatrics compared to adults. t(8;21)(q22;22) was significantly associated w…

We report a patient who presented with simultaneous T-lymphoblastic lymphoma, focal myeloid proliferation, and cutaneous cytotoxic T-cell lymphoma refractory to chemotherapy. The presence of myeloid and lymphoid lineages prompted genetic and molecular studies. A PDGFRA rearrangement was identified in all compartments: cutaneous, lymph node, and bone marrow. Treatment with imatinib resulted in an excellent response in cutaneous and systemic disease. We report the first case of a mature cutaneous T-cell lymphoma with PDGFRA rearrangement, expanding the spectrum of neoplasms associated with this genetic abnormality. Our case …

Fms-like tyrosine kinase (FLT3) plays an essential role in hematopoiesis [1]. Its somatic mutations occur in approximately one-third of patients with acute myeloid leukemia (AML), and have important prognostic and therapeutic implications in myeloid malignancies, especially in AML [2 –4]. Two common subtypes of FLT3 mutations have been well described: internal tandem duplication (ITD) in the juxtamembrane and a recurrent amino acid substitution or deletion in the activation loop of the tyrosine kinase (TKD).

Source: Leukemia ResearchCategory: Hematology Authors: Tags: Letter to the Editor Source Type: research

Sensitization of leukemia cells and their progenitors by granulocytic growth factors may modulate the cell cycle kinetics of blast cells and is a tool to enhance the efficacy of chemotherapy in younger adults with acute myeloid leukemia (AML) [1,2]. Resistance to chemotherapy may be related to the adherence of leukemia cells to the stromal environment via specific receptor and adhesion molecules.In this setting, the CXCR4/SDF-1 axis functions as a main regulator of homing and retention of both normal and malignant hematopoietic cells in the bone marrow (BM) [3].

Source: Leukemia ResearchCategory: Hematology Authors: Tags: Letter to the Editor Source Type: research

July 20, 2018 — The U.S. Food and Drug Administration today approved Tibsovo (ivosidenib) tablets for the treatment of adult patients with relapsed or refractory acute myeloid leukemia (AML) who have a specific genetic mutation. This is the first…

Mark Levis, MD, PhD, talks about new information about gilteritinib in FLT3 mutated acute myeloid leukemia (AML) at ASCO 2018.


Author: obr
Added: 07/20/2018

Source: Oncology TubeCategory: Cancer & Oncology Source Type: podcasts

Mark Levis, MD, PhD, explains the impact of measurable residual disease in the clinical outcomes of patients with relapsed or refractory acute myeloid leukemia (AML) at ASCO 2018


Author: obr
Added: 07/20/2018

Source: Oncology TubeCategory: Cancer & Oncology Source Type: podcasts

The FDA has approved the first-in-class agent ivosidenib, which targets mutations in the IDH1 gene in acute myeloid leukemia.FDA Approvals

The FDA approved a cancer drug from Agios Pharmaceuticals Inc. on Friday after a Phase 1 clinical study found it aided a small group of patients suffering from a rare type of leukemia.

Cambridge-based Agios (Nasdaq: AGIO) is developing treatments for several types of cancer, including acute myeloid meukemia, or AML. The rare blood and bone marrow disease worsens quickly and accounts for approximately one percent of cancer patients, according to the National Cancer Institute. Las t year, Agios won…





Source link

LEAVE A REPLY

Please enter your comment!
Please enter your name here